<DOC>
	<DOCNO>NCT01965613</DOCNO>
	<brief_summary>The purpose study determine treatment Xionix improve wound heal patient pyoderma gangrenosum .</brief_summary>
	<brief_title>A Phase II Open Label Study Xilonix Subjects With Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age : â‰¥18 2 . History pyoderma gangrenosum without systemic disease . 1 . Treatment biologicals ( include intravenous immunoglobulin ) investigational agent within last 4 week ( 5 halflives , whichever long ) . 2 . Treatment corticosteroid cyclosporine within last 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
</DOC>